Common questions
Frequently asked questions on retatrutide
Is retatrutide FDA approved?
No. Retatrutide is not FDA-approved as of mid-2026. It is an investigational compound in Phase 3 clinical trials under Eli Lilly's TRIUMPH program. A 2024 Clinical Diabetes profile describes retatrutide as the first triple agonist developed for anti-obesity therapy — that profile underscores its investigational status [14]. Approval requires completing Phase 3, submitting an NDA, and FDA review; none of those steps have occurred.
When will retatrutide be available?
No regulatory approval date has been announced. Phase 3 trials (TRIUMPH-1 and parallel) are ongoing as of mid-2026 [7][8]. After Phase 3 data are complete, Eli Lilly must file an NDA and await FDA review. Retatrutide holds Fast Track designation, which may accelerate review, but availability depends on trial outcomes, submission timing, and regulatory decisions that have not yet been made. See the dedicated retatrutide availability page for the full trial timeline.
Is retatrutide available?
Not as an approved medicine. Retatrutide is available only within clinical trials, where participants are enrolled, screened, and receive investigational product at no cost as part of the study protocol. Research-labeled material offered outside clinical trials is unregulated, of unverified identity and purity, and not manufactured to pharmaceutical standards. Obtaining retatrutide outside a trial does not provide access to the compound under safe or controlled conditions.
Is retatrutide legal?
Retatrutide is an unapproved new drug in the United States and most jurisdictions. It is not a scheduled controlled substance, but selling or distributing it as a drug without FDA approval violates the Federal Food, Drug, and Cosmetic Act. The FDA issued over fifty warning letters to retatrutide vendors in 2025 on these grounds. Possession for personal use occupies a legal gray area that varies by jurisdiction; it is not an FDA-approved substance.
What company makes retatrutide?
Retatrutide (LY3437943) was developed by Eli Lilly and Company. Eli Lilly holds the IND and is sponsoring the TRIUMPH Phase 3 program. The compound appears in Lilly's pipeline as its lead triple-agonist obesity and diabetes candidate. No other company holds approved rights to manufacture or distribute retatrutide.
Is Retatrutide approved in other countries?
No. Retatrutide is not approved in any country as of mid-2026. Eli Lilly is conducting trials in multiple countries, but approval is a country-by-country regulatory process that follows successful Phase 3 data and a separate regulatory submission in each jurisdiction. The European Medicines Agency, Health Canada, and other major regulators have not approved retatrutide.
What is Retatrutide's approval status in the US?
Investigational. Retatrutide is in Phase 3 clinical trials and has not been submitted to the FDA for approval. A 2025 Biomolecules review synthesizes the Phase 1/2 data and characterizes the up-to-~24 percent weight loss as a step-change versus prior incretin therapies, while explicitly noting the compound remains investigational [6]. Fast Track designation has been granted, which can shorten FDA review time but does not constitute approval.
Do you need a prescription for Retatrutide?
Retatrutide has no approved indication and no prescription pathway. It cannot be prescribed by a physician for clinical use because it is not an approved drug. Participants in clinical trials do not obtain prescriptions — they enroll in sponsored studies and receive the compound under protocol. Any entity claiming to offer retatrutide by prescription is not operating within the approved medical or regulatory framework.
Is Retatrutide available in the USA?
Only within clinical trials. ClinicalTrials.gov lists the TRIUMPH-1 trial (NCT05929066) enrolling at multiple US sites [7]. Outside of enrolling in a trial, retatrutide is not available as an approved product through any pharmacy, telehealth service, or prescriber in the United States. Gray-market research-labeled material is not the same as investigational pharmaceutical-grade retatrutide.
What does retatrutide do?
Retatrutide activates three hormone receptors simultaneously: GLP-1R (appetite suppression, glucose-dependent insulin secretion), GIPR (insulinotropic and adipose effects), and GCGR (energy expenditure, hepatic lipid clearance). A 2025 Biomolecules review describes the triple-receptor mechanism as the pharmacological basis for its superior weight-loss signal relative to single- and dual-agonist predecessors [6]. In a 48-week Phase 2 obesity trial, the 12 mg dose produced a mean −24.2 percent body-weight change [1].
How does retatrutide work?
Retatrutide is engineered to bind GLP-1R, GIPR, and GCGR with a single molecule. GLP-1R signaling suppresses appetite and augments insulin secretion. GIPR signaling adds an insulinotropic effect and influences adipose tissue metabolism. GCGR signaling — the mechanism shared with glucagon, the blood-sugar-raising hormone — increases energy expenditure and promotes hepatic fat breakdown. In a 48-week Phase 2 obesity trial, once-weekly retatrutide at 12 mg produced a mean −24.2 percent body-weight change versus −2.1 percent with placebo [1]. Cryo-EM structures confirm simultaneous engagement of all three receptors [3].
How to reconstitute retatrutide?
No standardized reconstitution protocol exists for retatrutide because it is not an approved product. In clinical trials, it is supplied as a pre-formulated solution by Eli Lilly's pharmaceutical supply chain [1][4]. Research-labeled retatrutide sold outside trials is of unverified identity and purity; the stability notes in the trial literature indicate the compound was studied only as a pharmaceutical-grade injectable, not as a reconstitutable lyophilized powder for research use. This site does not provide reconstitution instructions for an unapproved injectable compound.
How to take retatrutide?
In the published clinical trials, retatrutide was administered as a once-weekly subcutaneous (under-the-skin) injection [1][2][4]. Route, injection technique, dose escalation, and monitoring were all managed by clinical trial staff. Outside a clinical trial there is no approved protocol, no qualified clinical oversight, and no verified supply of the compound. This site describes the trial-design facts; it does not provide administration guidance for non-trial use.
How long does retatrutide take to work?
A 2025 Biomolecules review of the Phase 1/2 data notes that body-weight reductions in the Phase 2 obesity trial began to diverge from placebo within the first four to eight weeks at higher doses [6]. Steady-state plasma concentration with once-weekly dosing is reached in approximately three to four weeks, given the ~6-day half-life [4]. In the Phase 2 trial, weight loss continued to accumulate throughout the 48-week observation period at the highest dose, without clear plateau by week 48 [1].
Is retatrutide better than tirzepatide?
No head-to-head data are published yet. NCT06662383 is a Phase 3 active-comparator trial specifically designed to compare retatrutide with tirzepatide; it is ongoing and has not reported results [10]. Cross-trial comparisons of Phase 2 data show retatrutide's −24.2 percent weight reduction at 48 weeks exceeding tirzepatide's ~15–21 percent range, but different trial designs, populations, and dose ramps make these figures incomparable. The head-to-head trial will generate the direct evidence.
How much retatrutide per week?
In Phase 2 obesity trials, once-weekly subcutaneous doses of 1, 4, 8, and 12 mg were studied [1]. In Phase 2 type 2 diabetes trials, stepwise escalation from 0.5 mg to a maximum of 12 mg once weekly was used [2]. These are study-design facts from published trials, not dosing recommendations. Retatrutide is investigational; there is no approved dose.
How to mix retatrutide with bacteriostatic water?
In the clinical trials, retatrutide was supplied as a pharmaceutical-grade pre-formulated solution — not as a lyophilized powder requiring reconstitution with bacteriostatic water [1][4]. The mixing question arises because gray-market research-labeled peptides are commonly sold lyophilized and reconstituted by users. This site does not provide mixing instructions for any non-trial injectable compound; the compound's identity, purity, and sterility cannot be confirmed in gray-market research material.
How to switch from tirzepatide to retatrutide?
No clinical protocol for switching between these agents exists in the published literature. NCT06662383, the ongoing head-to-head trial, compares the two compounds but does not evaluate switching protocols [10]. Tirzepatide is an approved drug; retatrutide is not. Any transition between investigational and approved agents would require clinical oversight and monitoring — decisions that belong within a clinical trial or a supervised medical setting, not based on information from a research digest.
Is retatrutide a GLP-3?
No — there is no GLP-3 receptor. The "GLP-3" label is a popular misnomer. Retatrutide is a triple agonist at GIP, GLP-1, and glucagon receptors. Glucagon-like peptide-3 (GLP-3) is a peptide fragment produced during processing of proglucagon, but it does not have a characterized receptor or an established pharmacological action. Retatrutide's glucagon-receptor agonism is distinct from GLP-1 or GLP-2 activity, and the compound is accurately described as a GIP/GLP-1/glucagon tri-agonist [1][3].
What is retatrutide used for?
In clinical trials, retatrutide has been studied for obesity without type 2 diabetes [1], obesity with type 2 diabetes [2], obesity with MASLD (fatty liver disease) [5], obesity with established cardiovascular disease [8], cardiovascular and kidney outcomes [9], and in direct comparison with tirzepatide [10]. It is not approved for any indication. A 2025 Biomolecules review characterizes its intended therapeutic class as anti-obesity pharmacotherapy with secondary metabolic benefits [6].
What receptors does retatrutide target?
Retatrutide targets three class-B G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Cryo-EM structures published in 2024 confirm simultaneous binding at all three receptors [3]. Relative potency compared with endogenous hormones: ~8.9x native GIP at GIPR, ~0.4x native GLP-1 at GLP-1R, and ~0.3x native glucagon at GCGR [3].
How often do you take retatrutide?
In all published clinical trials, retatrutide was administered once weekly by subcutaneous injection [1][2][4]. The once-weekly schedule is supported by the ~6-day plasma half-life established in Phase 1b [4]. The Phase 3 TRIUMPH program also uses once-weekly subcutaneous dosing [7]. These are study-design facts; retatrutide is not an approved medicine and there is no prescribed frequency outside a clinical trial.